Somerset Indus Capital Partners, a healthcare-focused private equity firm, has exited all investments from its first fund, concluding a nine-year investment in a nutraceutical company through a buyback transaction. The firm is currently in the process of raising approximately $250 million for its third fund. This strategic exit marks a significant milestone for Somerset as it shifts focus toward new investment opportunities.